Without more proof of its effectiveness, Excellus is still considering the drug “investigational,” according to syracuse.com.
“Our health plan wants our members to have access to therapies that are safe, effective, and evidence-based as demonstrated by peer-reviewed clinical trials,” said Excellus Vice President Elizabeth Martin.
Aduhelm’s approval by the FDA is being reviewed by the HHS Office of Inspector General as of Aug. 4.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
